ICON Public (NASDAQ:ICLR) Given Outperform Rating at Leerink Partners

Leerink Partners reissued their outperform rating on shares of ICON Public (NASDAQ:ICLR) in a research report released on Tuesday,Benzinga reports. They currently have a $255.00 target price on the medical research company’s stock, down from their prior target price of $270.00.

ICLR has been the topic of a number of other reports. Robert W. Baird lowered shares of ICON Public from an “outperform” rating to a “neutral” rating and set a $340.00 price target on the stock. in a research note on Thursday, October 24th. StockNews.com lowered shares of ICON Public from a “buy” rating to a “hold” rating in a research note on Thursday, September 19th. Redburn Atlantic began coverage on shares of ICON Public in a research note on Monday, October 14th. They set a “neutral” rating and a $311.00 price target on the stock. Truist Financial cut their target price on shares of ICON Public from $363.00 to $295.00 and set a “buy” rating on the stock in a research note on Monday, October 28th. Finally, Leerink Partnrs upgraded shares of ICON Public to a “strong-buy” rating in a research note on Wednesday, September 18th. Four investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $292.45.

ICON Public Stock Up 0.7 %

Shares of ICLR opened at $214.25 on Tuesday. The company has a current ratio of 1.34, a quick ratio of 1.34 and a debt-to-equity ratio of 0.35. The firm has a market cap of $17.68 billion, a P/E ratio of 23.89, a price-to-earnings-growth ratio of 1.45 and a beta of 1.25. The company’s 50-day moving average price is $257.93 and its 200 day moving average price is $297.75. ICON Public has a 12-month low of $183.38 and a 12-month high of $347.72.

ICON Public (NASDAQ:ICLR) last issued its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.72 by ($0.37). The business had revenue of $2.03 billion for the quarter, compared to analysts’ expectations of $2.13 billion. ICON Public had a return on equity of 11.91% and a net margin of 9.00%. The firm’s revenue for the quarter was down 1.2% on a year-over-year basis. During the same quarter last year, the company earned $3.10 earnings per share. On average, sell-side analysts forecast that ICON Public will post 13.42 earnings per share for the current year.

Hedge Funds Weigh In On ICON Public

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Ashton Thomas Private Wealth LLC acquired a new position in ICON Public in the second quarter valued at approximately $54,000. ORG Partners LLC acquired a new position in ICON Public in the second quarter valued at approximately $59,000. GAMMA Investing LLC boosted its holdings in ICON Public by 50.0% in the second quarter. GAMMA Investing LLC now owns 261 shares of the medical research company’s stock valued at $82,000 after purchasing an additional 87 shares in the last quarter. EverSource Wealth Advisors LLC boosted its holdings in shares of ICON Public by 17.4% in the first quarter. EverSource Wealth Advisors LLC now owns 283 shares of the medical research company’s stock valued at $95,000 after acquiring an additional 42 shares during the period. Finally, Whittier Trust Co. of Nevada Inc. boosted its holdings in shares of ICON Public by 119.6% in the second quarter. Whittier Trust Co. of Nevada Inc. now owns 415 shares of the medical research company’s stock valued at $130,000 after acquiring an additional 226 shares during the period. 95.61% of the stock is owned by institutional investors and hedge funds.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.